ontemporary treatment of the memory disturbance in Alzheimer's disease is to boost declining cholinergic function, which is characteristic of this disease. 1, 2 The best way to do this so far is to stop the breakdown of acetylcholine (ACh) by inhibiting the enzyme acetylcholinesterase (AChE). The first available agent to stop the breakdown, tacrine (Cognex), was limited by its short duration of action, narrow dosing range, drug interactions, and liver toxicity. Donepezil (Aricept), rivastigmine (Exelon), and galantamine (Reminyl) all remove these unfavorable actions. They also inhibit AChE. Are these 3 drugs therefore all the same? In considering the answer, let's think of baseball great Yogi Berra's response to a question about whether he and his son were alike: "Our similarities are different." All 3 cholinesterase inhibitors are similar in that they inhibit AChE, yet they are also different in terms of other pharmacologic properties (Table 1) . These distinctions may help prescribers decide how to select one agent over another for different Alzheimer patients.
THE ROLE OF ACHE INHIBITION
AChE is a key inactivator of neuronally released ACh. It is now well known that inhibiting this enzyme can boost the action of ACh long enough to enhance cognition in Alzheimer patients, 1,2 which accounts not only for the mechanism of therapeutic action of donepezil, 3 rivastigmine, 4 and galantamine, 5, 6 but also for their side effects. Centrally enhanced ACh improves cognition and probably also improves disruptive behavior in Alzheimer patients. Peripherally enhanced ACh causes the gastrointestinal (GI) side effects characteristic of these agents, especially at initiation of dosing, such as nausea and diarrhea, and in some cases vomiting and weight loss. [1] [2] [3] [4] [5] [6] [7] Although all 3 agents appear to inhibit central AChE more than peripheral AChE, rivastigmine may be uniquely more selective for the form of AChE present in hippocampal neurons (G1) where cognition is important than for the form of AChE present in neurons in other parts of the brain such as pons (G4), which are not important for cognitive functioning. 4 
THE ROLE OF BUCHE INHIBITION
A second enzyme called butyrylcholinesterase (BuChE; sometimes also known as "pseudo" cholinesterase) also breaks down ACh. 4, 7 Normally, this enzyme seems to be more important in regulating ACh in peripheral tissues such as liver, plasma, and gut than in brain. How- THE ROLE OF ALLOSTERIC MODULATION OF NICOTINIC RECEPTORS Nicotinic cholinergic receptors may be especially important in regulating cognitive functions, such as attention, and in causing the release of more neurotransmitter from cholinergic neurons as well as from numerous other neurons that release dopamine, serotonin, γ-aminobutyric acid (GABA), glutamate, and norepinephrine. 8, 9 Nicotinic receptors can be regulated both by ACh and by allosteric modulators that help ACh. In much the same way that benzodiazepines help GABA at GABA A receptors, galantamine helps nicotinic cholinergic receptors by allosterically modulating them. 10 This modulation produces more "bang" from each ACh molecule and causes even more ACh release. 8, 9 Since nicotinic receptors are also located presynaptically on numerous other neurons that utilize various other neurotransmitters, this nicotinic modulating action of galantamine will lead to release of these other neurotransmitters throughout the brain. [8] [9] [10] The extent to which deficiencies of such neurotransmitters are restored could lead to improvement in functions mediated not only by ACh, but also by norepinephrine, dopamine, serotonin, glutamate, and GABA. Whether such theoretical actions will mean more improvement for cognition or for behaviors such as depression or anxiety associated with Alzheimer's disease is a provocative possibility that must await head-tohead trials of dual-action galantamine versus cholinesterase inhibitors that lack this property.
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SUMMARY
Three new cholinesterase inhibitors, donepezil, rivastigmine, and galantamine, all inhibit the enzyme AChE. Rivastigmine also inhibits BuChE, which could lead to additional benefits in late-stage Alzheimer's disease, but also cause more GI side effects at initiation of therapy.
Galantamine is also an allosteric modulator of nicotinic receptors, which could lead to additional efficacy for attention and for behaviors mediated by neurotransmitters other than ACh.
We are now entering an exciting era where the options for treating the devastating illness Alzheimer's disease are multiplying and creating a foundation upon which new therapies with new mechanisms of action can be built.
